For those seeking to potentially manage symptoms of this condition, Regenerative Medicine for Lupus is a natural alternative option.
Content Review: Michael Healey, M.Ed., C.A.S. Last Updated: September 2026
Lupus is a chronic autoimmune disease in which the immune system can attack healthy tissues. The most common form is systemic lupus erythematosus, or SLE. Lupus may affect the skin, joints, blood, kidneys, nervous system, heart, lungs, and other organs. Symptoms and severity vary widely. Some people have mild skin or joint symptoms, while others develop inflammation that affects major organs. Care should be tailored to the form of lupus, the organs involved, and the severity of disease activity.
Common Symptoms
There is no single cure for lupus, but established treatments can help control inflammation, reduce flares, protect affected organs, and improve quality of life. Treatment should be guided by a rheumatology clinician and may involve other specialists when the kidneys, nervous system, heart, lungs, or other organs are affected.
Standard Treatment Categories
Stem cell therapy for lupus and stem cell therapy for autoimmune conditions are being studied because mesenchymal stromal cells, or MSCs, may influence inflammatory and immune-system signaling. Researchers are evaluating different cell sources, doses, treatment schedules, background medications, and patient populations.
What Researchers Are Studying
Some studies also examine MSC-derived secretome, a cell-free product containing substances released by cells. Secretome research is distinct from stem cell treatment for lupus and should be interpreted separately.
Note: Stem cell therapies for lupus are not FDA-approved and are investigational. Early clinical studies have reported changes in disease activity, symptoms, and immune-system markers, and research continues across different cell products and treatment approaches.
How Stem Cell Therapy for SLE Is Being Studied
Research on stem cell therapy for SLE includes early clinical studies of MSC infusions and cell-free secretome products. Researchers are examining safety, changes in disease activity, immune-system markers, and outcomes related to organ involvement. Studies are evaluating different cell sources, doses, treatment schedules, background medications, and delivery methods. This work is helping identify the treatment approaches and patient groups that warrant continued clinical study.
2025: MSC-Derived Secretome Reported Short-Term Disease-Activity and Immune-Marker Changes
Umbilical Cord Mesenchymal Stem Cell-Derived Secretome as a Potential Treatment for SLE: A Double-Blind Randomized Controlled Trial — Read Study
This double-blind trial enrolled 29 women with moderate lupus disease activity. Participants received weekly intramuscular injections of umbilical-cord-MSC-derived secretome or placebo for six weeks. The researchers reported differences in disease activity and selected immune markers between groups during short-term follow-up, with no severe adverse events reported. This study adds to clinical research on cell-free, MSC-derived secretome products for people with SLE.
2025: Allogeneic UC-MSCs Were Generally Well Tolerated in Severe Lupus
Allogeneic Umbilical Cord-Derived Mesenchymal Stromal Cells as Treatment for Systemic Lupus Erythematosus: A Single-Centre, Open-Label, Dose-Escalation, Phase I Study — Read Study
This phase I study enrolled eight people with severe, treatment-resistant lupus who received escalating doses of allogeneic umbilical-cord-derived MSCs. The investigators reported that the infusions were generally tolerated and tracked changes in disease activity during follow-up. These findings provide early clinical information on dose-escalation UC-MSC treatment for people with severe SLE.
2022: UC-MSC Infusion Reported Clinical and Immune-System Changes in Treatment-Refractory Lupus
Safety, Immunological Effects and Clinical Response in a Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells in Patients With Treatment-Refractory SLE — Read Study
This phase I trial included six women with active, treatment-refractory lupus who received a single umbilical-cord-derived MSC infusion. At 24 weeks, some participants met the study’s lupus responder endpoint. The researchers also reported changes in selected immune-cell measures and no serious treatment-related adverse events. These results add to continued clinical research on UC-MSC infusion for people with active SLE.
2017: UC-MSCs Were Studied Alongside Standard Treatment for Lupus Nephritis
A Randomised Double-Blind, Placebo-Controlled Trial of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cell for Lupus Nephritis — Read Study
This placebo-controlled trial enrolled 18 people with class III or IV lupus nephritis. All participants received intensive standard immunosuppressive treatment and were randomly assigned to receive umbilical-cord-derived MSCs or placebo. At the study assessment, renal remission occurred in 75% of the MSC group and 83% of the placebo group. Disease activity, kidney function, and other outcomes were also tracked in both groups. This trial contributes important comparative research on UC-MSC treatment alongside standard therapy for lupus nephritis.
For people with lupus who want to understand emerging research, stem cell therapy for lupus and other regenerative medicine approaches may be topics to discuss with a healthcare provider. A consultation can help review your diagnosis, organ involvement, medications, treatment history, and goals. It can also clarify whether an investigational approach is something to discuss further with your treating rheumatologist.
At Stemedix, we take a patient-centered approach to regenerative medicine, informed by emerging clinical research. Our team reviews your medical history, current treatment plan, and goals to help determine whether an investigational regenerative approach may be appropriate to explore.
This page is for educational purposes only and does not constitute medical advice.
Stem cell, secretome, and regenerative medicine therapies for lupus are not FDA-approved for this use. Research findings do not guarantee individual results.
Always consult a qualified healthcare professional before making treatment decisions.
U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. FDA
Speak with a Care Coordinator today for a more accurate assessment of your condition and therapy options.
Stemedix speaks with Patricia about her experience with Stemedix stem cell treatment for Lupus.
Our Board-Certified Physicians specialize in regenerative medicine. They stay abreast of the latest developments in stem cell research. Each patient is screened and reviewed before being approved for therapy.
Each patient is thoroughly reviewed to ensure their safety for treatment. The physicians will then determine potential benefit candidacy. If approved, a customized treatment plan is offered for the patient.
Stemedix can help coordinate patients with necessary wheelchair transportation, medical equipment, and Care Giving services as needed during their stay. Your Care Coordinator is available for questions and assistance.
Could PRP Help With More Than Back Pain? Lower back pain can make even simple activities, like sitting at a desk, bending down, or enjoying a walk, uncomfortable. For some people, the problem begins with the spinal discs, which act as cushions between the bones of the spine. When these discs begin to wear down,…
Could Umbilical Cord Blood Help Support Movement? For children with cerebral palsy, everyday movements such as sitting, standing, and walking can require extra effort. Cerebral palsy affects how the brain controls movement and posture, making physical therapy and other supportive treatments an important part of daily life. Researchers are now exploring whether umbilical cord blood…
Compare autologous and donor-derived MSC research for cartilage, discs and tendons, including clinical findings, safety and evidence limitations.
Contact us today and let Stemedix provide professional service accompanied by one of our Care Coordinators to ensure you have the best experience possible!